Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial - Quiz - MDSpire

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

  • By

  • Priscilla Merriam

  • James J. Morrow

  • Emanuele Mazzola

  • Nicole L. Solimini

  • Prafulla C. Gokhale

  • Ping Chi

  • Alice P. Chen

  • Mark Agulnik

  • Melissa Burgess

  • Scott M. Schuetze

  • Neeta Somaiah

  • Brian A. Van Tine

  • Seth M. Pollack

  • Gabriel Tinoco

  • Jonathan Trent

  • Breelyn A. Wilky

  • Nicola Bothwick

  • Benjamin K. Eschle

  • Vivian Nguyen

  • Jan H. Beumer

  • Noushin Rastkari

  • Shahanawaz Jiwani

  • Peter I-Fan Wu

  • Lorraine Pelosof

  • Matthew L. Hemming

  • Geoffrey I. Shapiro

  • George Demetri

  • Bradley Bernstein

  • Suzanne George

  • May 26, 2026

  • 0 min

Share

Original Source(s)

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

  • by Priscilla Merriam, James J. Morrow, Emanuele Mazzola, Nicole L. Solimini, Prafulla C. Gokhale, Ping Chi, Alice P. Chen, Mark Agulnik, Melissa Burgess, Scott M. Schuetze, Neeta Somaiah, Brian A. Van Tine, Seth M. Pollack, Gabriel Tinoco, Jonathan Trent, Breelyn A. Wilky, Nicola Bothwick, Benjamin K. Eschle, Vivian Nguyen, Jan H. Beumer, Noushin Rastkari, Shahanawaz Jiwani, Peter I-Fan Wu, Lorraine Pelosof, Matthew L. Hemming, Geoffrey I. Shapiro, George Demetri, Bradley Bernstein, Suzanne George

  • May 26, 2026

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma